Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study;Epidemiología de las resistencias genotípicas del VIH-1 en Valencia. Estudio de cuatro años

Revista Espanola de Quimioterapia

Volumn 20, Issue 3, 2007, Pages 346-353

  Molina, J M ^a   Cordoba J ^a   Gil, A ^a   Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antiretroviral; HIV; Mutations; Protease inhibitors; Resistance; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; LAMIVUDINE; LOPINAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; SPAIN; VIRUS GENE; VIRUS LOAD; VIRUS RESISTANCE;

ALGORITHMS; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION, MISSENSE; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; SPAIN; VIRAL LOAD;

EID: 36949004765     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Young, B., Johnson, S., Bahktiari, M. y cols. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 1998; 178: 1497-1501.
2. Puig, T., Pérez-Olmeda, M., Rubio, A. y cols. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000; 14: 727-732.
3. Gutiérrez, F., Moltó, J., Escolano, C. y cols. Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy. Med Clin 2000; 115: 401-404.
4. Cozzi, Lepri A., Sabin, C.A., Staszewski, S. y cols. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis 2000; 181: 1143-1147.
5. De Grottola, V., Dix, L., D'Aquila, R. y cols. The relation between antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standarized data analysis plan. Antivir Ther 2000; 5: 41-48.
6. Lorenzi, P., Milos, O., Hirschel, B. y cols. Impact of drug resistance on virologic response to salvage therapy. AIDS 1999; 13: 17-21.
7. Harrigan, P.R., Hertogs, K., Verbiest, W. y cols. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13: 1863-1871.
8. Cordoba J., Otero M.C., Laínez B. y cols. Virus de la inmunodeficiencia humana y resistencias. Rev Esp Quimioterap 1998; 11: 152-156.
9. Molina, J.M., Córdoba, J., Gobernado, M. Resistencias de VIH-1 a los antiretrovirales en la Comunidad Valenciana: Mutaciones y sensibilidades. Rev Esp Quimioterap 2003; 16: 308-312.
10. Baxter, J.D., Schapiro, J.M., Boucher, C.A. y cols. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006; 80: 1794-1801.
11. Molla, A., Korneyeva, M., Gao, Q. y cols. Ordered accumulation of mutations in HIV protease confers resistance to ritornavir. Nat Med 1996; 2: 760-766.
12. Boucher, CA., Cammack, N., Schipper, P. y cols. High-level resistance to(-) enantiomeric 2′-deoxy-3′thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-2234.
13. Young, S.D., Britcher, S.F., Tran, L.O. y cols. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitors of the human immunodeficiency virus type I reverse transcriptase. Antimicrob Agents Chemother 1995; 39: 2602.